Information Provided By:
Fly News Breaks for February 7, 2017
GWPH
Feb 7, 2017 | 09:37 EDT
Cantor Fitzgerald analyst Elemer Piros believes GW Pharmaceuticals' Phase 2 glioblastoma multiforme data today are "very encouraging" and further support of the "multi-potent effect of cannabinoid-based medicines across an array of neurological condition." The analyst reiterates a Buy rating on GW shares with a $208 price target. The stock in early trading is up 93c to $121.69.
News For GWPH From the Last 2 Days
There are no results for your query GWPH